U.S. market Open. Closes in 5 hours 56 minutes

LOGC | LogicBio Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for LOGC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (17%)

Company Industry
P/E Ratio (TTM) -0.77 -23.05
PEG Ratio (TTM) -0.03 15.47
P/S Ratio (TTM) 1.11 49.46
P/B Ratio (TTM) 1.11 18.87
P/FCF Ratio (TTM) -0.69 -3.27
Price to 5YR AVG Earnings Ratio -0.15 -3.55
Price to 5YR AVG FCF Ratio -0.48 -9.37

Profitability (25%)

Company Industry
ROA (TTM) -138.37% -5.14%
ROE (TTM) -109.05% 16.69%
Net Profit Margin (TTM) -141.03% -1,583.93%
ROIC 5YR AVG 162.45% 15.15%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 27.49% -3,218.29% -1,926.47%
Revenue -36.84% -5.98% -28.06%
Net Income 26.55% -610.92% -364.33%
Cash Flow 23.77% -1,105.43% -648.29%

Health (30%)

Company Industry
Current Ratio (TTM) 31.80 6.13
Quick Ratio (TTM) 31.80 5.85
D/E Ratio (TTM) N/A -15.81
Interest Coverage (TTM) N/A -1.57
Piotroski F-Score 1 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.02 0.17
Shares Outstanding Growth 5YR AVG 123.28% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙